protein

Human Apolipoprotein CIII

MBS318091

0.1 mg

210 USD

Native Protein

Human Apolipoprotein CIII

Apolipoprotein CIII (Apo CIII)

Human Apolipoprotein CIII (Apo CIII)

apolipoprotein C-III; Apolipoprotein C-III; apolipoprotein C-III; apo-CIII; apoC-III; apolipoprotein C3; OTTHUMP00000043270; OTTHUMP00000069353; apolipoprotein C-III; Apolipoprotein C3

APOC3; APOC3; APOCIII; MGC150353

APOC3_HUMAN

Human plasma, Very Low Density Lipoprotein (VLDL)

99

Apolipoprotein CIII (Apo CIII)

>=95% pure (SDS-PAGE)

Purified, Lyophilized. Reconstitute with 59.9ul distilled water.

1.67mg/ml (prior to lyophilization)

Store at -20 degree C. Avoid multiple freeze/thaw cycles.

Inactivation: Not applicable

Buffer: Lyophilized from 10mM NH4HCO3, pH 7.4. Preservative: No. Lyophilized: Yes. Warnings: All human source materials have tested non-reactive for HBsAg, anti-HCV, anti-HBc and negative for anti-HIV 1 and HIV 2 by FDA required tests. No test guarantees a product to be non-infectious. Therefore, all material derived from human fluids o

Purified Lipoproteins

4557323

NP_000031.1

NM_000040.1

P02656

10,852 Da

Chylomicron-mediated Lipid Transport Pathway (106157); HDL-mediated Lipid Transport Pathway (106158); Lipid Digestion, Mobilization, And Transport Pathway (106111); Lipoprotein Metabolism Pathway (106156); Metabolism Of Lipids And Lipoproteins Pathway (160976); PPAR Signaling Pathway (83042); PPAR Signaling Pathway (450); Statin Pathway (198852)

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq]

Function: Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles. Subcellular location: Secreted. Tissue specificity: Constitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine. Post-translational modification: O-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan. Ref.9 Ref.10. Involvement in disease: Defects in APOC3 may be a cause of hyperalphalipoproteinemia (HYPALIP) [. MIM:143470]. Affected individuals show high levels of alpha-lipoprotein (high density lipoprotein/HDL). Ref.11. Sequence similarities: Belongs to the apolipoprotein C3 family.

0.1 mg

210 USD